Feb 21, 2023 14:02 JST

Source: Eisai

Dissolution of Bracco-Eisai Joint Venture

TOKYO, Feb 21, 2023 - (JCN Newswire) - Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. As a result, Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Co., Ltd. as of April 1, 2023.

Bracco and Eisai established Bracco-Eisai in 1990 with the aim of establishing a contrast agent business in Japan. The companies launched the non-ionic contrast agent Iomeron and the macrocyclic non-ionic contrast agent ProHance for MRI in 1994, and have worked together in a friendly partnership for more than 30 years. After comprehensive consideration, the companies decided to dissolve the joint venture in order to respond quickly and flexibly to the changing environment surrounding the healthcare industry and achieve sustainable contributions to patients through these products.

Regarding Iomeron and ProHance, products that Eisai and Bracco-Eisai have co-promoted thus far, Eisai and Bracco-Japan will continue to co-promote these products between April 1, 2023 and March 31, 2024, with Bracco-Japan as the domestic manufacturer and Eisai as the distributor. Bracco Japan will exclusively commercialize the products from April 1, 2024.

"The Asia-Pacific region plays a leading role in diagnostic imaging and is expected to grow faster than other global markets," said Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging S.p.A. "Bracco has had a considerable presence in Japan for many years and will continue to strengthen its relationships with customers in order to better understand and meet the needs of customers in Japan. We will continue to provide better diagnostic imaging technology and services."

"We are deeply grateful to Bracco, with whom we have worked together for more than 30 years since Bracco-Eisai's founding to contribute to patients in the field of diagnostic imaging." said Haruo Naito, Chief Executive Officer at Eisai Co., Ltd. "Based on our human health care concept, Eisai will continue to play a role in providing information on both Iomeron and ProHance until the end of March 2024, and will take all possible measures to ensure a smooth transfer of operations, so that Bracco Japan can maintain its contribution to patients."

Media Inquiries:

Bracco Imaging S.p.A.
Bracco Imaging Media Relations
TEL: +39-340-9016191

Bracco Eisai Co.,Ltd
Public Relations
TEL: +81-(0)3-5319-3381

Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
June 08 2023 12:32 JST
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
June 02 2023 11:20 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26 2023 13:15 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25 2023 20:02 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24 2023 17:03 JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 20 2023 09:20 JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
May 16 2023 08:27 JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
May 08 2023 10:15 JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
April 06 2023 17:32 JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
April 04 2023 12:23 JST
More Press release >>

Latest Press Release

More Latest Release >>